Valeant Pharma (VRX) Reports Q1 EPS of $2.36; Announces CFO Transition

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. SPY
5. ACN
6. IBM
7. PFE
8. TSLA
9. DPZ
10. NVDA

Go back to Valeant Pharma (VRX) Reports Q1 EPS of $2.36; Announces CFO Transition

Valeant Pharmaceuticals Reports First Quarter 2015 Financial Results

April 29, 2015 6:00 AM EDT

LAVAL, Quebec, April 29, 2015 /PRNewswire/ --

2015 First Quarter Results

Total Revenue $2.2 billion; an increase of 16% over the prior year despite negative foreign exchange impact of $140 million Excluding negative impact of foreign exchange and last year's divestiture of the aesthetics injectable business, revenue increased 27% over the prior year Same Store Sales Organic Growth was 15%, driven by: Growth from launch brands, including BioTrue Multipurpose Solution, BioTrue ONEday Contact Lens, Jublia, Luzu, and Ultra Contact Lens Double digit... More

Valeant Announces CFO Succession Plan And Additional Executive Appointment

April 29, 2015 6:00 AM EDT

LAVAL, Quebec, April 29, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that Howard B. Schiller has advised the Company of his decision to step down as Chief Financial Officer once a successor is appointed. In order to facilitate a smooth transition, Mr. Schiller will remain in his current position as the search for his replacement proceeds.  With the support of Valeant's Board of Directors, Mr. Schiller will remain on the Valeant Board and, with the Board's continued recommendation,... More